Reference Interval:
0.0-10.0 U/mL
|
| Interpretive Data: |
The NMP22® assay is intended as an aid in the management of patients with transitional cell carcinoma of the urinary tract (TCC/UT). It is used after surgical treatment to identify patients with residual or rapidly recurring TCC/UT.
Values obtained with different assay methods should not be used interchangeably. ARUP uses the Matritech NMP22® Test Kit which is an enzyme immunoassay (EIA) method.
|
| CPT Code(s): |
86316
|
Cross References: |
Bladder Tumor Associated Antigen (NMP22®)
, Nuclear Matrix Protein (NMP22®)
|